EcoDrugPlus

C-X-C Motif Chemokine Receptor 1

Ensembl ID : ENSMMMG00000018180
Gene Symbol: CXCR1
3 Cross references
158 Possible Orthologues:

C-X-C Motif Chemokine Receptor 2

Ensembl ID : ENSMMMG00000018174
Gene Symbol: CXCR2
3 Cross references
237 Possible Orthologues:

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSMMMG00000021192
Gene Symbol: CXCR4
3 Cross references
283 Possible Orthologues:

Dna Methyltransferase 1

Ensembl ID : ENSMMMG00000015887
Gene Symbol: DNMT1
3 Cross references
206 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSMMMG00000015112
Gene Symbol: TOP1
3 Cross references
270 Possible Orthologues:

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSMMMG00000007405
Gene Symbol: TOP2A
3 Cross references
209 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSMMMG00000021487
Gene Symbol: TOP2B
3 Cross references
208 Possible Orthologues:

Dna-(Apurinic Or Apyrimidinic Site) Lyase-Like

Ensembl ID : ENSMMMG00000004030
Gene Symbol: LOC107150834
2 Cross references
211 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSMMMG00000016500
Gene Symbol: EML4
3 Cross references
209 Possible Orthologues:

Eph Receptor A2

Ensembl ID : ENSMMMG00000021393
Gene Symbol: EPHA2
3 Cross references
124 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSMMMG00000016294
Gene Symbol: EPHA3
3 Cross references
215 Possible Orthologues:

Eph Receptor B4

Ensembl ID : ENSMMMG00000011848
Gene Symbol: EPHB4
3 Cross references
166 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).